William Blair & Company
GEVA

William Blair & Company’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

William Blair & Company’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-6,650
Closed -$430K – 2102
2013
Q4 		$430K Buy
+6,650
New +$395K ﹤0.01% 1630

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

William Blair & Company's GEVA Position: Q1 2014 in Review

William Blair & Company sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2014, closing a stake of 6,650 shares — an estimated $430K sold.

William Blair & Company first reported a position in GEVA in Q4 2013 and held it in 1 quarter. The position peaked at $430K in Q4 2013. 115 funds tracked by Wall St. Rank hold GEVA as of Q1 2014.

  • William Blair & Company reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2014 after selling out during the quarter.
  • William Blair & Company sold 6,650 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2014, an estimated $430K.
  • William Blair & Company first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2013 and held it in 1 quarter.
  • William Blair & Company's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $430K in Q4 2013.
  • 115 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2014.

Based on William Blair & Company's 13F filing for Q1 2014, filed 6 May 2014.